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Kidney failure (stage 5 Chronic Kidney Disease = CKD) is an important health problem, considering its increasingly high incidence and p revalence besides the very expensive medication, including renal r eplacement therapy, that the patients with kidney failure must undergo. Globally, in 1966 there were approximately one million patients with CKD underwent renal replacement therapy (hemodialysis, peritoneal dialysis, or kidney transplantation); and this number will increase to 2 million in 2010 (1) . Cardiovascular disease is often seen in patients with CKD either at the pre-dialysis phase or mainly at the dialysis phase. Cardiovascular disease is the main cause of death in patients with CKD, with its estimated incidence 10 to 100 times greater than that in the population without CKD (2) .
In addition to the conventional/traditional factors of cardiovascular disease such as smoking, diabetes, hypertension, dyslipidemia, and obesity at all stages of kidney disease, there are non-traditional risk factors or uremia-related risk factors such as increased homosysteine, C-reactive p rotein (CRP), asymmetric dimethylarginine (ADMA) concentration, occurrence o f microinflammation, p roteinuria, and increased oxidative stress, all of which contribute to the progression of these cardiovascular disease risks (2, 3) .
Clinical evidences have indicated that not all patients with CKD in the early stage progressed into renal failure, and that the p ercentage o f early stage CKD that progressed to renal failure varied among patients. It was suggested that several factors contributed to the progression of early stage chronic kidney disease into kidney failure, and intervention on the risk factors if done at the early stage could slow down progression; in fact in several conditions it could even totally stop progression into kidney failure (1).
Homocysteine i s an amino acid-containing sulphydril group that originates from the essential amino acid methionin that comes in great abundance from vegetable fat. The metabolic pathway that changes methionine to homosysteine is very important for many biomolecules t o maintain their normal functions, including DNA, p roteins, phospholipids and neurotransmitters (4) . Homocysteine concentration elevates along with worsening of the kidney function (2, 5) . In several studies homocysteine was proposed as a cardiovascular risk factor. Asymmetric dimethylarginine (ADMA) i s an arginine form modified post-translationally from all cells during protein modification process. ADMA is a guanidine compound synthesized in endothelial cells. ADMA concentration elevates along with the worsening of the kidney function (6) . ADMA is a competitive inhibitor f rom endothelial nitric oxide synthase (eNOS). eNOS is an enzyme that modifies L-arginine to become nitric oxide (NO). NO plays an important role in maintaining normal endothelial functions as vasodilator, anti thrombosis, and anti proliferation. Elevated ADMA can diminish NO availability, thus ADMA is suggested t o be an important cardiovascular risk factor (7) .
Several studies using e xperimental animals and clinical studies have indicated there was a close correlation between total plasma homocycsteine and plasma ADMA concentration (8) .
Homocysteine is an important part of methylation process. S-adenosylomethionine (SAM) is a methyl donor that enables arginine methylation and produce S-adenosylhomocysteine (SAH); in turn i t can be modified into homocysteine. Results of several studies suggested that ADMA produced by human endothelial cells was upregulated in the presence of methionine or homocysteine and inhibited by metyltransferaseinhibiting SAH.
In situations where homocysteine level increases, the concentration of intracellular SAH can elevate. Since SAH is a potent inhibitor to transmethylation reactions, its accumulation can cause macromolecules hypomethylation. According to this mechanism, DNA hypomethylation occurs in hyperhomocysteinemic patients with end-stage kidney disease. In the later condition, production of ADMA by endothelial cells is inhibited through incubation by SAH (9) . Two isoforms o f dimethylarginine dimethylhidrolase (DDAH) have been identified: DDAH-I is mostly found in the neural tissues, whereas DDAH-II dominates i n peripheral and vascular tissues. DDAH is an intracellular protein whose role in several disease conditions has been studied. Because its enzymatic role is to selectively hydrolyze ADMA to form L-citrulline and dymetilamine, r educed enzymatic DDAH expression or activity can elevate the concentration of ADMA (9) .
Homocysteine can inhibit DDAH activity, probably because of its interaction with important cysteine residue in active enzyme site. Several studies have suggested the possibility that every e xisting correlation between homocysteine and cardiovascular risk might possibly indicate a correlation reflection between ADMA and cardiovascular risk (6 
Results
Based on data of the interviews, physical examinations, biochemical examinations, the individual characteristics of the study subjects could be summarized as shown in Table 1 .
Note: p = probability Correlation between tHcy and ADMA concentration by linear regression showed that there was no significant correlation between ADMA concentration with tHcy with r2 = 0.19 and p = 0.499. Correlation analysis between ADMA and tHcy concentration at each CKD level indicated the presence of positive correlation among them at CKD stage 2 and 3, however, inverse correlation between tHcy and ADMA concentration started to occur at stage 4 In this study there w ere 20 DM patients and 55 non-DM patients. Higher tHcy and ADMA concentration means were observed but they were no significant difference between non-DM patients and DM patients. 
.75 mol/L was the cutoff value for PKV, with logistic binary test on the variables GF (estimation), age, sex, presence of DM, hypertension, and dyslipidemia, then it would show that sex and age were the statistically most significant variables (p 0.004 and 0.012) of the elevation of ADMA concentration. y sex variable, there were 32 female sub ects (42.7%) and 43 male sub ects (57.3%) involved in this study. f the 32 female sub ects, 24 sub ects (75%) were with ADMA concentration > 0.75 mol/L (mean of age 55 years) and sub ects (25%) with ADMA concentration 0.75 mol/L (mean of age years). Meanwhile, of 43 male sub ects there were 1 sub ects (41.9%) with ADMA concentration > 0.75 mol/L (mean of age 52 years) and 25 sub ects (5 .1%) with ADMA concentration 0.75 mol/L (mean of age 5 years).
esult of the t test showed there was no statistically significant d ifference between the age mean of the female study sub ects with elevated ADMA concentration and that of the female study sub ects with non-elevated ADMA (p=0.092). In contrast, it was found that the mean of age of the male study sub ects with elevated ADMA concentration was significantly different from that of the male sub ects having nonelevated ADMA concentration (p=0.011). Discussion able 3 indicated that in CKD patients there was a difference of the mean of tHcy concentration according to CKD severity levels, in which at later CKD stage, the mean of tHcy concentration was significantly higher (p=0.000) than at earlier stage.
CKD i s almost often correlated with hyperhomosysteinemia.
Plasma homocysteine concentration i s closely correlated with decrease o f LFG concentration in which elevated tHcy concentration starts t o occur a t LFG < 6 0 ml/minute/1.73 m2. Prevalence of hyperhomocysteinemia in CKD is about 85-100% according to CKD severity. The relationship mechanism o f LFG with elevated plasma homocysteine concentration is not yet fully understood (10) .
In general, patients with kidney disease have normal methionine, betaine and vitamin B plasma level, increased AdotMet, Ado H cy, cysteine and sulfate, and decreased serine concentration. It seems that in patients with kidney disease, the plasma homocysteine concentration has close correlation with plasma folate, AdoHcy and cysteine concentrations. The mechanism that can explain this phenomenon may be related with the inhibited homocysteine remethylation and impaired cysteine excretion
The mechanism o f protein re-methylation inhibition is supported by results of studies that have indicated that successful t reatment regimen could lower its concentration in CKD.
Impairment of cysteine excretion was reported by Suliman et al who suggested that in CKD inhibition of cysteinesulphunic acid decarboxylation, which is synthesis of cysteine and taurine alteration, caused elevation of hyperhomocysteine concentration.
A study using stable isotope method to observe systemic homocysteine metabolism in patients with kidney failure and in healthy individuals found that remethylation flux and total transmethylation were reduced in CKD patients.
Two mechanisms may explain the increase of plasma homocysteine concentration and r educed flux through methylation cycle in patients with kidney failure: 1) the presence of primary defect in homocysteine metabolism can result in homocysteine transulfuration impairment. On the other side, higher homocysteine concentration r esults in the slower methylation cycle b y inhibiting transmethylation.; 2) the occurrence o f pimary defect can r esult in homocysteine transmethylation. Of this study, the hypothesis was that an unknown substance -able to filtrate the glomerular sites-regulated homocysteine excretion through re-methylation or transulfuration. Table 4 indicated that in CKD stage 2 to 4 there was a tendency of insignificant elevation of the mean ADMA concentration (p=0.210). In CKD stage 5, there was lower ADMA concentration mean.
ADMA is a rginine form modified posttranslationally and synthesized b y all cells during protein modification process. ADMA is well-known as an independent predictor for cardiovascular morbidity and mortality and its status as cardiovascular risk factor has been generally accepted. NOS competitive inhibition most likely becomes ADMA effect mechanism o n the c ardiovascular system, though nitric oxide (NO)-related mechanisms shouldn't be ignored. Only free ADMA, and not its bind protein, is able to inhibit NOS. Since NOS is an intracellular cell, concentration of free intracellular ADMA -not its plasma concentration -is associated in NOS inhibition. Free ADMA is formed exclusively through sequence of protein arginine residue methylation, followed by the protein proteolysis. There are two paths for ADMA clearance f rom cells. First, ADMA is degadraded enzymatically by DDAH to become citrulline and dimethylamine. Second, the path enhances ADMA transport from the cell to plasma through cationic acid transporters (CAT) in its plasma membrane. In addition, clearance f rom plasma compartment occurred through two routes: renal excretion and uptake by cell through CAT. Thus, CAT activity is involved in cellular release and ADMA uptake, and consequently, it plays important role in intracellular and inter-organ ADMA transportation. Both the kidney and liver seem to become important organs in ADMA clearance from plasma (9) . The actual mechanism that results in ADMA accumulation in CKD patients i s not yet fully understood. One known mechanism is that reduced ADMA excretion has a linear relationship with reduced kidney function. In CKD, plasma ADMA concentration is increased to 1 -3 mol/L (11).
A study suggested that i n intravenous dimethylarginine supplementation, 66% of filtrated SDMA would b e reabsorbed, whereas only 5 % of filtrated ADMA would be reabsorbed.
Result of a study on molecular mechanism of increased ADMA plasma concentration in CKD using model mice with p rogressive CKD suggested that disregulation on enzyme PRMT and DDAH occurred as a result of oxidative stress. This mechanism was supported by the evidences that : (1) gene expression PRMT type I i s increased b y oxidized L DL i n endothelial cells (EC) cultured by a redox-regulated mechanism; (2) DDAH activities in EC and smooth muscles is decreased in high-glucose condition, which is blocked by an antioxidant, superoxide dismutase. It is known that oxidative stress is increased in CKD patients. In addition to oxidative stress, there are uremic toxic like homocysteine and AGE products that decrease DDAH activity, which can cause disregulation of these enzyme.
The factors that have caused the insignificance of the ADMA elevation in our present study may possibly relate to the not-observed random variables like smoking, duration o f hypertension, type of hypertension medication, and duration of diabetes and anti-diabetes therapy.
In this study the mean value o f ADMA concentration was found to be lower in the earlier stages of CKD than in stage 5. This will be explained in more detail in the next analysis of correlation of homocysteine and ADMA.
Result of the correlation analysis between tHcy and ADMA using linear regression showed that the data distribution among two variables indicated quadratic model, in which there was ADMA elevation simultaneously with tHcy up to the concentration of tHcy of about 20 mol/L, then decreased. The analysis found no significant correlation between ADMA and tHcy concentration.
Correlation analysis between ADMA and tHcy concentration in each CKD severity level indicated positive correlation in CKD stage 2 and 3, however, inverse correlation between tHcy and ADMA concentration started to appear in stage 4.
Interaction between homocysteine and ADMA was estimated t o occur b y metabolic r elationship between ADMA and transfer methyl r eactions. ADMA is p roduced f rom methylated p rotein of arginin r esidue. PRMT type 1 utilized AdoMet=S-adenocylmethionine/SAM a s a methyl donor and produced AdoHcy=S-adenocylhomocysteine/SAH (and finally homocysteine) as its by product. Since ADMA is synthesized from proteolysis of methylated protein, the hypothesis was that increased SAMdependent p rotein methylation could r esult in increased ADMA production and increased homocysteine. This hypothesis was supported by an experimental study using animals (monkeys) supplemented with methionine-rich and folate-deficient food, the results of which indicated there was elevation of ADMA plasma concentration. Methionine-rich and folate-deficient food caused three times greater elevation of plasma tHcy and ADMA. It also suggested that the higher the ADMA concentration, the closer its correlation with tHcy; and occurrance vasodilation impairment was dependant on the endothelium of the carotid arteries of the animals (8) .
In a clinical study, eight hours after supplementing standard oral methionine (100 mg/kg), plasma ADMA increased from 1.4 0.2 to 2.0 0.2 M (p<0.05), plasma tHcy increased from 6.9 1.6 to 28.4 3.5 M (p<0.05), and brachial artery vasodilation decreased by 80%. Brachial artery vasodilation had inverse correlation with plasma ADMA (p<0.05) and has linear correlation with L-arginine/ADMA ratio (p<0.01). Similar fi ndings were reported by Stuhlinger et al (8) .
Evidence o f the metabolic correlation between homocysteine and ADMA was also r eported f rom studies with cell culture. Incubation of endothelial cells with L-methionine or L-homocysteine produced dosage-dependant ADMA elevations on the culture media (8) .
Several control studies have r eported the relationship between hyperhomocysteinemia and plasma ADMA elevation in human subjects with coronary artery disease, peripheral arterial disease, and stroke (8) .
It wasn't fully understood how ADMA increased in hyperhomocysteinemia. Initially, it was hypothesized that the conditions that could cause homocysteine elevation included methionine-rich food, which could elevate SAM intracellular level and thus increase ADMA production by supporting SAMdependant PRMT activities. However, currently this mechanism is considered not likely, since typically hyperhomocysteinemia causes elevation of SAH level in tissue, but it is not true with the level of SAM . Although hyperhomocysteinemia probably does not increase PRMT activity with the increase of cellular SAM level, however, i t is still possible that u p regulation of PRMT expression occurs in hyperhomocysteinemia (8) .
Other possible mechanism of ADMA elevation in hyperhomocysteinemia is decreased kidney function and decreased DDAH activity-that metabolize ADMA to citrulline. Homocysteine is reported to be able to inhibit DDAH activity in vitro, perhaps through an oxidative reaction with its active site residue (8) .
a n I -synthase (CBS) that resulted in high homocysteine, there was decreased mRNA concentration from two main DDAH enzymes: DDAH-1 and DDAH-2. This indicated that homocysteine could regulate DDAH expression and activity (8) .
All recent studies on cell cultures in animals and human subjects r eported that ADMA was metabolically associated with homocysteine. This indicated the influence of ADMA elevation on vascular dysfunction during hyperhomocystinemia. Homocysteine could increase ADMA by inhibiting DDAH activity or by stimulating oxidative stress which i n turn wouldl inactivate DDAH oxidative. In contrast, homocysteine could elevate ADMA by stimulating endoplasmic reticulum stress and apoptosis that r esulted i n elevation of p rotein proteolysis containing methylarginine residue.
Correlation analysis between ADMA and tHcy concentration in each CKDseverity level indicated a positive correlation in CKD stage 2 and 3, however, inverse correlation between tHcy and ADMA concentration started t o appear in CKD stage 4. This can b e explained that in situation in which homocysteine elevated, SAH intracellular level could increase. Since SAH is a potent inhibitor for transmethylation reactions, its accumulation can result in macromolecules hypomethylation.
Consistent with this mechanism, DNA hypomethylation i s observed on hyperhomocysteinemic patients with kidney problems. It was also observed that ADMA production by endothelial cells was inhibited by SAH incubation (9) .
Appropriateness o f an assay method i s very important since i t affects the correlation power between ADMA and homocysteine. In our study, ADMA was assayed by ELISA method, in which control precision among assays could be obtained (by coefficient of variation) by 14% of the control concentration range of 0.24 -0.58, all of which indicated that ADMA is closely metabolically associated with homocysteine. These evidences indicated a model in which ADMA elevation could b e an integrating mechanism for vascular dysfunction i n hyperhomocysteinemia. Homocysteine could increase ADMA by inhibiting DDAH activity through a direct chemical r eaction with cysteine active site or by stimulating oxidative stress and DDAH oxidative inactivation as the result. On the other hand, homocysteine could elevate ADMA by stimulating endoplasmic reticulum stress and apoptosis that resulted in proteolysis elevation of protein containing methylarginine residue. ADMA accumulation in endothelial cells could inhibit eNOS to cause decreased N O products and endothelial dysfunction. Release o f eNOS sequence triggered by ADMA or other oxidants like peroxinitrite could accelerate superoxide p roduction and further decreased NO availability (8) .
Result of the correlation analysis between ADMA and homocysteine showed no significant correlation between ADMA and tHcy concentration. This perhaps can be explained that in several studies conducted, some fundamental questions should yet to be answered concerning the pathophysiology of ADMA in hyperhomocysteinemia. Although most clinical studies have indicated that ADMA plasma increased in individuals with hyperhomosisteinemia, some of them have indicated that hyperhomosisteinemia wasn't always correlated with significant elevation of plasma ADMA. Similar differences were noted in animal models with hyperhomocysteinemia. There was three times greater elevation of plasma ADMA in hyperhomocysteinemic monkey, but only slight elevation occurred in plasma ADMA of CBS-deficient mice with hyperhomocysteinemia.
The correlation analysis between ADMA and tHcy concentration in each C KD severity level showed positive correlation between them in CKD stage 2 and 3, however, inverse correlation between tHcy and ADMA concentration started to appear in stage 4. This could be explained that in situations in which homocysteine increased, intracellular SAH level could elevate. Since SAH is a potent inhibitor for transmethylation reactions, its accumulation could result in macromolecules hypomethylation. According to this mechanism, DNA hypomethylation is observed in hyperhomocysteinemic patients with end-stage kidney disease. Also observed that ADMA production by endothelial was inhibited b y SAH-mediated incubation (9) .
In this study, the assay on ADMA was performed by ELISA method, of which the control precision between assays (between day coefficient variation) was Teerlink in 2005 in his study reported that Pearson coefficient correlation distribution was obtained after 100 simulation experiments, thus to reveal that by increasing CV (coefficient correlation) in ADMA assay could r esult in weakening of the estimation o f correlation power between ADMA and homocysteine. T eerlink emphasized that with a very considerable number of study subjects, all those simulation experiments would still obtain very significant correlation. However, with less than 100 study subjects, its correlation would be statistically insignificant (p 0.05) i n all simulation experiments, with r 0.2. In contrast with the crucial effect of CV elevation on the ADMA assay, artificial elevation of CV in homocysteine assay up to 10% most likely would not affect the correlation power.
In this study, there were 20 DM patients and 55 non-DM patients studied. The correlation analysis found higher mean of tHcy and ADMA concentrations, but it was insignificant in the non-DM patients compared with than in the DM patients (p = 0.246 and p = 0.322). This probably was due to some variables being not observed in the study such as duration of diabetes and anti-diabetes medication as well as the fact that analysis was not carried out on each of the CKD stages in DM and non-DM groups.
If tHcy concentration > 12 mol/L was categorized as abnormal and this concentration considered as cutoff value for CKD risk, b y logistic binary test on the variables LFG, age, sex, p resence o f DM, hypertension and dyslipidemia, i t was found that LFG (estimation) was the most important variable (p = 0.000) of homocysteine concentration elevation. This can be explained that homocysteine is mainly excreted by kidney while ADMA in only 5%, thus LFG is very essential part of homocysteine concentration.
If ADMA concentration > 0.75 mol/L (age mean 55 years) was categorized a s abnormal (kit insert reagent), then from this study it was found 33 5 7 . Analysis on sex in this study showed 32 female subjects were with ADMA concentration 0.75 mol/L (mean age 55 years) and 8 subjects (25%) with ADMA concentration < 0.75 mol/L (mean age 58 years). From t test, it was found the age mean for the female subjects were with ADMA concentration that elevated insignificantly with the female subjects with nonelevated ADMA (p=0.092).
Other result of the t test showed that age means for male subjects with elevated ADMA were significantly different in male subjects with non-elevated ADMA (p=0,011). This could be explained by several clinical studies which have reported convincingly o f the role of ADMA in the progression of cardiovascular disease. In a cohort study on 25 patients with kidney failure, ADMA and age were found to be the strongest predictor for c ardiovcascular events and total mortality, even after improvements on traditional and new risk factors had been made. Another study with control case design indicated that middle-age, non-smoking men with ADMA concentration in the highest quartile had experienced four times greater risk elevation in acute coronary events than other quartile (9) .
Our present study revealed that 24 (75%) of the female subjects had ADMA concentration elevation, while in the male subjects, ADMA elevation occurred in 18 of the male subjects (41.9%). This was probably associated with the r ole o f women's hormone -especially estrogen -in suppressing ADMA concentration, in this study probably most of the female subjects were already in the menopause phase, thus their estrogen hormone had decreased and consequently elevated ADMA.
This study r evealed that there was an increase in homocysteine and ADMA concentration according to CKD severity level. In CKD stage 2 to 4 there was a tendency of elevation of the ADMA concentration mean, but mean of ADMA concentration was lower in stage 5. The positive correlation between homocysteine and ADMA concentration was showed b y ADMA 0 2 o t p u n o i t a v e l e y c H t h t i w y l t n e r r u c n o c n o i t a v e l e mol/L, and then decreased in stage 4. e also found out that there was negative correlation between tHcy and ADMA concentration that started to appear in stage 4. This can be explained that in situations in which homocysteine increases, intracellular AH level can increase as well (hydrolysis reaction of AH to Hcy is reversible). ince AH is a potent inhibitor for transmethylation, its accumulation can inhibit ADMA production by endothelial cells.
From these results, w e suggest that a cohort study with equally distributed population number at every stage of CKD and a correlation study between hyperhomosisteinemia and ADMA, RMT activity, DDAH and O formation than gold standard in endothelial dysfunction measurement of ow mediated dilatation (FMD) should be conducted.
This study brings forward the opportunity o f finding or utilizing therapy target in hyperhomocysteinemic patients due to CKD in order to inhibit the effects of ADMA on endothelial dysfunction and progression of arteriosclerosis.
Conclusion

